Handel Cerevel Therapeutics Holdings, Inc. - CERE CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.11 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 26.94 |
Åben* | 25.72 |
1-Års Ændring* | -4.56% |
Dagens Spænd* | 25.72 - 27.24 |
52-Ugers Spænd | 19.86-41.46 |
Gennemsnitlig Volumen (10 dage) | 830.10K |
Gennemsnitlig Volumen (3 måneder) | 12.64M |
Market Cap | 3.67B |
P/E-forhold | -100.00K |
Udestående aktier | 156.66M |
Omsætning | N/A |
EPS | -2.32 |
Dividend (Udbytte %) | N/A |
Beta | -100.00K |
Næste indtjeningsopgørelse | May 8, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 26.95 | 1.81 | 7.20% | 25.14 | 27.30 | 25.14 |
Jun 28, 2022 | 26.94 | -0.93 | -3.34% | 27.87 | 29.13 | 26.80 |
Jun 27, 2022 | 28.99 | 0.89 | 3.17% | 28.10 | 29.70 | 27.49 |
Jun 24, 2022 | 28.08 | -0.17 | -0.60% | 28.25 | 29.09 | 27.63 |
Jun 23, 2022 | 28.54 | 3.28 | 12.98% | 25.26 | 28.60 | 25.26 |
Jun 22, 2022 | 26.05 | 1.34 | 5.42% | 24.71 | 26.24 | 24.71 |
Jun 21, 2022 | 25.15 | -0.32 | -1.26% | 25.47 | 25.47 | 24.03 |
Jun 17, 2022 | 23.86 | 0.20 | 0.85% | 23.66 | 24.42 | 23.16 |
Jun 16, 2022 | 22.85 | -1.18 | -4.91% | 24.03 | 24.03 | 22.07 |
Jun 15, 2022 | 24.53 | 0.31 | 1.28% | 24.22 | 24.87 | 23.33 |
Jun 14, 2022 | 24.22 | 0.64 | 2.71% | 23.58 | 25.12 | 23.54 |
Jun 13, 2022 | 23.87 | -0.71 | -2.89% | 24.58 | 24.67 | 23.20 |
Jun 10, 2022 | 25.82 | -0.27 | -1.03% | 26.09 | 27.04 | 25.60 |
Jun 9, 2022 | 27.99 | 0.51 | 1.86% | 27.48 | 28.92 | 27.48 |
Jun 8, 2022 | 28.49 | 1.30 | 4.78% | 27.19 | 29.41 | 27.19 |
Jun 7, 2022 | 28.72 | 3.24 | 12.72% | 25.48 | 28.84 | 25.48 |
Jun 6, 2022 | 25.86 | -1.88 | -6.78% | 27.74 | 28.32 | 25.13 |
Jun 3, 2022 | 27.78 | 1.02 | 3.81% | 26.76 | 28.51 | 26.76 |
Jun 2, 2022 | 26.98 | 1.06 | 4.09% | 25.92 | 27.80 | 25.30 |
Jun 1, 2022 | 26.37 | 0.40 | 1.54% | 25.97 | 26.76 | 25.02 |
Cerevel Therapeutics Holdings, Inc. Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | |
---|---|---|---|
Total omsætning | 0 | 0 | 0 |
Driftsindtægter | -220.098 | -149.116 | 0 |
Fortyndelsesændring | 0 | ||
Fortyndet Netto Indkomst | -225.334 | -148.271 | 0 |
Totale Driftsudgifter | 220.098 | 149.116 | |
Salgs/Generelle/Admin. Udgifter, Total | 58.243 | 45.813 | |
Forskning & Udvikling | 161.855 | 103.303 | |
Renteindkomst (Udgift), Netto Ikke-Drift | 0.157 | 0.224 | |
Andre, Netto | -5.393 | -3.274 | |
Netto Indkomst Før Skat | -225.334 | -152.166 | |
Netto Indkomst Efter Skat | -225.334 | -152.142 | |
Netto Indkomst Før Ekstra Ting | -225.334 | -152.142 | |
Netto Indkomst | -225.334 | -152.142 | |
Total Adjustments to Net Income | 0 | 3.871 | |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -225.334 | -148.271 | |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -225.334 | -148.271 | |
Fortyndet Vægtet Gennemsnit Aktier | 136.577 | 73.6433 | |
Fortyndet EPS Uden Ekstraordinære Ting | -1.64987 | -2.01337 | |
Fortyndet Normaliseret EPS | -1.64987 | -2.01337 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total omsætning | 0 | 0 | 0 | 0 | 0 |
Totale Driftsudgifter | 72.53 | 64.49 | 54.527 | 50.51 | 50.571 |
Salgs/Generelle/Admin. Udgifter, Total | 17.507 | 16.649 | 14.368 | 13.216 | 14.01 |
Forskning & Udvikling | 55.023 | 47.841 | 40.159 | 37.294 | 36.561 |
Driftsindtægter | -72.53 | -64.49 | -54.527 | -50.51 | -50.571 |
Renteindkomst (Udgift), Netto Ikke-Drift | 0.295 | 0.119 | 0.013 | 0.01 | 0.015 |
Andre, Netto | 3.941 | 5.316 | -7.545 | -2.739 | -0.425 |
Netto Indkomst Før Skat | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Netto Indkomst Efter Skat | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Netto Indkomst Før Ekstra Ting | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Netto Indkomst | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Fortyndet Netto Indkomst | -68.294 | -59.055 | -62.059 | -53.239 | -50.981 |
Fortyndet Vægtet Gennemsnit Aktier | 147.985 | 147.392 | 144.022 | 127.482 | 127.226 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.46149 | -0.40067 | -0.4309 | -0.41762 | -0.40071 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.46149 | -0.40067 | -0.4309 | -0.41762 | -0.40071 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | |
---|---|---|---|
Totale Nuværende Aktiver | 578.017 | 390.56 | |
Likvider og Kortsigtede Investeringer | 565.688 | 383.623 | |
Likvider & Lignende | 193.018 | 383.623 | |
Prepaid Expenses | 11.6 | 6.777 | |
Other Current Assets, Total | 0.729 | 0.16 | |
Total Assets | 688.919 | 445.273 | |
Property/Plant/Equipment, Total - Net | 51.7 | 48.624 | |
Property/Plant/Equipment, Total - Gross | 54.266 | 48.706 | |
Accumulated Depreciation, Total | -2.566 | -0.082 | |
Other Long Term Assets, Total | 6.933 | 6.089 | |
Total Current Liabilities | 42.538 | 29.548 | |
Accounts Payable | 11.298 | 4.993 | |
Accrued Expenses | 30.865 | 24.282 | |
Notes Payable/Short Term Debt | 0 | 0 | |
Other Current Liabilities, Total | 0.375 | 0.273 | |
Total Liabilities | 110.19 | 60.753 | |
Total Long Term Debt | 33.54 | 0 | |
Other Liabilities, Total | 34.112 | 31.205 | |
Total Equity | 578.729 | 384.52 | |
Common Stock | 0.015 | 0.013 | |
Additional Paid-In Capital | 1195.94 | 775.417 | |
Retained Earnings (Accumulated Deficit) | -616.244 | -390.91 | |
Total Liabilities & Shareholders’ Equity | 688.919 | 445.273 | |
Total Common Shares Outstanding | 147.72 | 127.124 | |
Kortsigtede Investeringer | 372.67 | ||
Long Term Investments | 52.269 | ||
Long Term Debt | 33.54 | ||
Other Equity, Total | -0.986 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 553.55 | 578.017 | 675.029 | 331.782 | 349.811 |
Likvider og Kortsigtede Investeringer | 542.944 | 565.688 | 669.676 | 327.06 | 343.287 |
Likvider & Lignende | 91.764 | 193.018 | 669.676 | 327.06 | 343.287 |
Prepaid Expenses | 10.004 | 11.6 | 5.257 | 4.597 | 6.362 |
Other Current Assets, Total | 0.602 | 0.729 | 0.096 | 0.125 | 0.162 |
Total Assets | 618.552 | 688.919 | 733.48 | 391.004 | 408.104 |
Property/Plant/Equipment, Total - Net | 52.663 | 51.7 | 51.98 | 51.92 | 51.784 |
Property/Plant/Equipment, Total - Gross | 56.299 | 54.266 | 53.526 | 52.552 | 51.876 |
Accumulated Depreciation, Total | -3.636 | -2.566 | -1.546 | -0.632 | -0.092 |
Other Long Term Assets, Total | 4.411 | 6.933 | 6.471 | 7.302 | 6.509 |
Total Current Liabilities | 35.318 | 42.538 | 30.8 | 29.257 | 34.151 |
Accounts Payable | 8.183 | 11.298 | 5.445 | 4.986 | 7.755 |
Accrued Expenses | 26.442 | 30.865 | 24.928 | 23.939 | 26.241 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.693 | 0.375 | 0.427 | 0.332 | 0.155 |
Total Liabilities | 97.053 | 110.19 | 104.4 | 97.117 | 68.068 |
Total Long Term Debt | 28.324 | 33.54 | 38.612 | 32.242 | 0 |
Other Liabilities, Total | 33.411 | 34.112 | 34.988 | 35.618 | 33.917 |
Total Equity | 521.499 | 578.729 | 629.08 | 293.887 | 340.036 |
Common Stock | 0.015 | 0.015 | 0.015 | 0.013 | 0.013 |
Additional Paid-In Capital | 1207.36 | 1195.94 | 1186.79 | 789.004 | 781.914 |
Retained Earnings (Accumulated Deficit) | -684.538 | -616.244 | -557.189 | -495.13 | -441.891 |
Total Liabilities & Shareholders’ Equity | 618.552 | 688.919 | 733.48 | 391.004 | 408.104 |
Total Common Shares Outstanding | 148.183 | 147.72 | 147.136 | 127.585 | 127.325 |
Long Term Debt | 28.324 | 33.54 | 38.612 | 32.242 | |
Other Equity, Total | -1.334 | -0.986 | -0.533 | ||
Kortsigtede Investeringer | 451.18 | 372.67 | |||
Long Term Investments | 7.928 | 52.269 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | |
---|---|---|---|
Netto indkomst/Startlinje | -225.334 | -152.142 | |
Likvider Fra Driftsaktiviteter | -178.546 | -117.802 | |
Likvider Fra Driftsaktiviteter | 2.731 | 0.397 | |
Ikke-Likvide Ting | 28.516 | 16.236 | |
Ændringer i Driftskapital | 15.541 | 17.707 | |
Likvider fra Investeringsaktiviteter | -435.661 | -18.892 | |
Kapitaludgifter | -10.503 | -18.892 | |
Likvider fra Financieringsaktiviteter | 423.602 | 440.835 | |
Financiering af Cash-Flow-Ting | -0.355 | 440.835 | |
Netto Ændring i Likviditet | -190.605 | 304.141 | |
Andre Investerings-Cash-Flow-Ting, Total | -425.158 | ||
Udstedelse (Pensionering) af Aktier, Netto | 392.707 | ||
Udstedelse (Pensionering) af Gæld, Netto | 31.25 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -68.294 | -225.334 | -166.279 | -104.22 | -50.981 |
Cash From Operating Activities | -67.648 | -178.546 | -125.802 | -82.026 | -36.418 |
Cash From Operating Activities | 1.118 | 2.731 | 1.644 | 0.664 | 0.063 |
Non-Cash Items | 4.935 | 28.516 | 27.551 | 14.084 | 6.377 |
Changes in Working Capital | -5.407 | 15.541 | 11.282 | 7.446 | 8.123 |
Cash From Investing Activities | -38.542 | -435.661 | -9.431 | -8.243 | -4.66 |
Capital Expenditures | -2.197 | -10.503 | -9.431 | -8.243 | -4.66 |
Cash From Financing Activities | 2.603 | 423.602 | 421.286 | 33.706 | 0.742 |
Issuance (Retirement) of Stock, Net | 2.854 | 392.707 | 390.036 | 2.571 | 0.742 |
Net Change in Cash | -103.587 | -190.605 | 286.053 | -56.563 | -40.336 |
Financing Cash Flow Items | -0.251 | -0.355 | 0 | -0.115 | |
Issuance (Retirement) of Debt, Net | 31.25 | 31.25 | 31.25 | ||
Other Investing Cash Flow Items, Total | -36.345 | -425.158 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Bain Capital Private Equity, LP | Private Equity | 38.704 | 60632356 | 0 | 2022-12-31 | LOW |
Pfizer Inc | Corporation | 17.4581 | 27349211 | 0 | 2022-08-16 | MED |
Fidelity Management & Research Company LLC | Investment Advisor | 14.5879 | 22852917 | 67107 | 2022-12-31 | LOW |
Perceptive Advisors LLC | Private Equity | 4.1567 | 6511727 | 0 | 2022-12-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.8476 | 6027510 | 164460 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 3.027 | 4742044 | 1202 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2049 | 3454078 | 288570 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.1858 | 3424220 | 704948 | 2022-12-31 | LOW |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 1.8304 | 2867451 | -445882 | 2022-12-31 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 1.6 | 2506464 | 7316 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.2806 | 2006068 | 4631 | 2022-12-31 | MED |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.2128 | 1900000 | -100000 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7686 | 1204108 | 69847 | 2022-12-31 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 0.7349 | 1151321 | -231639 | 2022-12-31 | LOW |
Lord, Abbett & Co. LLC | Investment Advisor | 0.7159 | 1121566 | 35610 | 2022-12-31 | MED |
Hood River Capital Management LLC | Investment Advisor | 0.5896 | 923638 | 27066 | 2022-12-31 | MED |
Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 0.5716 | 895509 | -87899 | 2022-12-31 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.4755 | 744853 | 7881 | 2022-12-31 | LOW |
Novalis LifeSciences LLC | Private Equity | 0.4043 | 633350 | 0 | 2022-03-31 | |
Fidelity Institutional Asset Management | Investment Advisor | 0.3602 | 564215 | 34460 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cerevel Therapeutics Holdings, Inc. Company profile
Om Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. er en biofarmaceutisk virksomhed i den kliniske fase. Virksomheden kombinerer en forståelse af sygdomsrelateret biologi og hjernens neurokredsløb med kemi og centralnervesystemet (CNS), receptorfarmakologi for at opdage og designe nye behandlinger. Virksomheden beskæftiger sig med udvikling af nye behandlinger for neurovidenskabelige sygdomme, herunder skizofreni, epilepsi og Parkinsons sygdom. Virksomhedens produktkandidater omfatter CVL-231, Darigabat, Tavapadon, CVL-871 og CVL-936. Virksomhedens produktkandidat CVL-231 til behandling af skizofreni. Darigabat til behandling af både epilepsi og angst. Tavapadon er en dopamin D1/D5 partiel agonist til behandling af Parkinsons sygdom i tidlige og sene stadier. Produktkandidaten CVL-871 til behandling af demensrelateret apati. Produktets CVL-936 til behandling af stofmisbrugsforstyrrelser (SUD).
Industry: | Bio Therapeutic Drugs |
222 Jacobs Street
Suite 200
CAMBRIDGE
MASSACHUSETTS 02141
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com